Verve Therapeutics (VERV)
About
Business overview of Verve Therapeutics (VERV)
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
Key Insights
Critical company metrics and information
Share Price
$6.01Market Cap
$508.83 MillionTotal Outstanding Shares
84.66 Million SharesTotal Employees
255Dividend
No dividendIPO Date
June 17, 2021SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQType
Common StockPhone Number
(978) 501-3026Address
201 brookline avenue, Boston, MA, 02215Homepage
https://www.vervetx.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $-157.53 Million |
| Net Cash Flow From Financing Activities, Continuing | $201.43 Million |
| Net Cash Flow From Investing Activities, Continuing | $36.44 Million |
| Net Cash Flow From Operating Activities | $-157.53 Million |
| Net Cash Flow, Continuing | $80.34 Million |
| Net Cash Flow | $80.34 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Basic Earnings Per Share | $-2.46 |
| Costs And Expenses | $250.94 Million |
| Income/Loss From Continuing Operations After Tax | $-197.03 Million |
| Depreciation and Amortization | $6.57 Million |
| Income Tax Expense/Benefit | $308,000.00 |
| Diluted Average Shares | $85.85 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Current Liabilities | $42.64 Million |
| Noncurrent Assets | $107.45 Million |
| Fixed Assets | $19.63 Million |
| Noncurrent Liabilities | $112.71 Million |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Cash | $539.90 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2025 Financhle. All Rights Reserved.